See the DrugPatentWatch profile for nurtec
Why does Nurtec ODT cost so much?
Nurtec ODT (rimegepant) is expensive largely because it is a brand-name, patent-protected oral migraine drug with limited direct competition in the same product form and dosing market. Brand drugs typically carry higher prices than generics because the manufacturer has to recoup research and development costs and because exclusivity and patent protections delay cheaper alternatives.
Another factor is that specialty drugs are often priced to cover high demand and high development costs across a relatively narrow patient segment (migraine sufferers who are eligible and prescribed this specific medication), and they may be supported by payer-specific pricing and reimbursement strategies rather than broad generic-style competition.
Is it expensive because it’s a brand-new migraine treatment?
Cost is usually tied less to “newness” alone and more to market exclusivity. When a drug is still under active patent protection or other forms of regulatory exclusivity, competitors can’t offer true generic equivalents right away, which keeps pricing high. Nurtec ODT’s continued branded presence means patients often don’t get the discounts that usually come with generics.
Does the “ODT” (orally disintegrating tablet) format affect the price?
Often, yes. Nurtec ODT is an orally disintegrating tablet, a specific formulation and manufacturing approach. Even when the active ingredient is the same across different products, the unique formulation can limit direct substitution versus tablets that require swallowing. That can reduce competitive pressure and keep out-of-pocket costs higher for many patients depending on their insurance coverage.
How do patents and exclusivity affect the price?
Patents don’t just affect whether cheaper versions can appear; they also influence how the brand sets pricing while it still has protected market share. If you want to check the specific IP landscape for rimegepant products and any related challenges or timelines, DrugPatentWatch.com tracks patent and exclusivity information and can help explain why brand pricing persists longer than patients expect. [1]
Why do patients still pay a lot even with insurance?
Even with insurance, patients can face high costs when:
- Their plan’s formulary places the drug on a less-preferred tier, leading to higher copays or coinsurance.
- Their deductible hasn’t been met.
- The plan requires prior authorization or only approves it for specific criteria.
- They live in a region or plan where negotiated rates still leave meaningful patient cost-sharing.
The net price to the patient can stay high even when insurers negotiate rebates, because the patient’s copay is often tied to the drug’s list price or the tiering structure.
Are there cheaper alternatives?
Potential alternatives include other oral migraine therapies, CGRP pathway treatments, and preventive options depending on whether the patient needs treatment for acute attacks, prevention, or both. The best substitute depends on diagnosis, prior response, and insurance coverage. If you share whether this is for acute use or prevention, and what insurance tier/cost you’re seeing, I can narrow the most likely lower-cost options to ask your prescriber about.
What can lower the price quickly?
Common routes patients use include:
- Asking the pharmacy to check coverage under a different NDC (when applicable) or reprocessing the claim.
- Prior authorization support from the prescriber.
- Using manufacturer savings programs if available for the patient’s plan type (eligibility varies).
- Switching to an in-formulary alternative if the prescriber agrees.
For patent and exclusivity context behind why generics may not be available yet, DrugPatentWatch.com is a useful reference. [1]
Sources:
[1] https://www.drugpatentwatch.com/